Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines

Veterinary Immunology and Immunopathology

Volumn 137, Issue 3-4, 2010, Pages 208-216

  Takeuchi, Yoshinori ^a   Fujino, Yasuhito ^a   Watanabe, Manabu ^b   Nakagawa, Takayuki ^a   Ohno, Koichi ^a   Sasaki, Nobuo ^a   Sugano, Sumio ^b   Tsujimoto, Hajime ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Dog; KIT; Mutation; Stem cell factor

Indexed keywords

DASATINIB; STEM CELL FACTOR RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; AUTOPHOSPHORYLATION; CELL CULTURE; DOG; IMMUNOSTIMULATION; MAST CELL; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DOG DISEASES; DOGS; MASTOCYTOSIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-KIT; RNA, MESSENGER; STEM CELL FACTOR;

CANIS FAMILIARIS;

EID: 77956268346     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2010.05.009     Document Type: Article

References (38)

1. Akin C., Jaffe E.S., Raffeld M., Kirshenbaum A.S., Daley T., Noel P., Metcalfe D.D. An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells. Am. J. Clin. Pathol. 2002, 118:242-247.
2. Bodemer C., Hermine O., Palmerini F., Yang Y., Grandpeix-Guyodo C., Leventhal P.S., Hadj-Rabia S., Nasca L., Georgin-Lavialle S., Cohen-Akenine A., Launay J.M., Barete S., Feger F., Arock M., Catteau B., Sans B., Stalder J.F., Skowron F., Thomas L., Lorette G., Plantin P., Bordigoni P., Lortholary O., Prost Y., Moussy A., Sobol H., Dubreuil P. Pediatric mastocytosis is a clonal disease associated with D(816)V and other activating c-KIT mutations. J. Invest. Dermatol. 2010, 130:804-815.
3. Broudy V.C. Stem cell factor and hematopoiesis. Blood 1997, 90:1345-1364.
4. Corbacioglu S., Kilic M., Westhoff M.A., Reinhardt D., Fulda S., Debatin K.M. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 2006, 108:3504-3513.
5. de Paulis A., Minopoli G., Arbustini E., de Crescenzo G., Dal Piaz F., Pucci P., Russo T., Marone G. Stem cell factor is localized in, released from, and cleaved by human mast cells. J. Immunol. 1999, 163:2799-2808.
6. Dobson J.M., Scase T.J. Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. J. Small Anim. Pract. 2007, 48:424-431.
7. Downing S., Chien M.B., Kass P.H., Moore P.E., London C.A. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am. J. Vet. Res. 2002, 63:1718-1723.
8. Gari M., Goodeve A., Wilson G., Winship P., Langabeer S., Linch D., Vandenberghe E., Peake I., Reilly J. c-Kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br. J. Haematol. 1999, 105:894-900.
9. Gerber H.P., Malik A.K., Solar G.P., Sherman D., Liang X.H., Meng G., Hong K., Marsters J.C., Ferrara N. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417:954-958.
10. Gilfillan A.M., Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol. Rev. 2009, 228:149-169.
11. Gleixner K.V., Rebuzzi L., Mayerhofer M., Gruze A., Hadzijusufovic E., Sonneck K., Vales A., Kneidinger M., Samorapoompichit P., Thaiwong T., Pickl W.F., Yuzbasiyan-Gurkan V., Sillaber C., Willmann M., Valent P. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp. Hematol. 2007, 35:1510-1521.
12. Hahn K.A., Ogilvie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., Dubreuil P., Moussy A., Hermine O. Masitinib is safe and effective for the treatment of canine mast cell tumors. J. Vet. Intern. Med. 2008, 22:1301-1309.
13. Ishiguro T., Kadosawa T., Mori K., Takagi S., Okumura M., Fujinaga T. Establishment and characterization of a new canine mast cell tumor cell line. J. Vet. Med. Sci. 2001, 63:1031-1034.
14. Isotani M., Ishida N., Tominaga M., Tamura K., Yagihara H., Ochi S., Kato R., Kobayashi T., Fujita M., Fujino Y., Setoguchi A., Ono K., Washizu T., Bonkobara M. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J. Vet. Intern. Med. 2008, 22:985-988.
15. Letard S., Yang Y., Hanssens K., Palmerini F., Leventhal P.S., Guery S., Moussy A., Kinet J.P., Hermine O., Dubreuil P. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol. Cancer Res. 2008, 6:1137-1145.
16. Liao A.T., Chien M.B., Shenoy N., Mendel D.B., McMahon G., Cherrington J.M., London C.A. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002, 100:585-593.
17. Lin T.Y., Thomas R., Tsai P.C., Breen M., London C.A. Generation and characterization of novel canine malignant mast cell line CL1. Vet. Immunol. Immunopathol. 2009, 127:114-124.
18. London C.A. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim. Med. 2009, 24:106-112.
19. London C.A., Galli S.J., Yuuki T., Hu Z.Q., Helfand S.C., Geissler E.N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 1999, 27:689-697.
20. London C.A., Kisseberth W.C., Galli S.J., Geissler E.N., Helfand S.C. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. J. Comp. Pathol. 1996, 115:399-414.
21. London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., Bergman P.J., Couto G.C., Mauldin G.N., Michels G.M. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin. Cancer Res. 2009, 15:3856-3865.
22. Ma Y., Longley B.J., Wang X., Blount J.L., Langley K., Caughey G.H. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J. Invest. Dermatol. 1999, 112:165-170.
23. Miettinen M., Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 2006, 130:1466-1478.
24. Ohmori K., Kawarai S., Yasuda N., Tanaka A., Matsuda H., Nishimura R., Sasaki N., Tsujimoto H., Masuda K. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells. Vet. Immunol. Immunopathol. 2008, 126:43-53.
25. Pryer N.K., Lee L.B., Zadovaskaya R., Yu X., Sukbuntherng J., Cherrington J.M., London C.A. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin. Cancer Res. 2003, 9:5729-5734.
26. Roskoski R. Signaling by Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem. Biophys. Res. Commun. 2005, 337:1-13.
27. Roskoski R. Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem. Biophys. Res. Commun. 2005, 338:1307-1315.
28. Santos S.C., Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004, 103:3883-3889.
29. Scharpfenecker M., Fiedler U., Reiss Y., Augustin H.G. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J. Cell Sci. 2005, 118:771-780.
30. Shin I.S., Nam M.J., Park S.J., Youn H.Y., Han H.R. Cloning of canine GM-CSF and SCF genes. J. Vet. Sci. 2001, 2:159-166.
31. Shull R.M., Suggs S.V., Langley K.E., Okino K.H., Jacobsen F.W., Martin F.H. Canine stem cell factor (c-kit ligand) supports the survival of hematopoietic progenitors in long-term canine marrow culture. Exp. Hematol. 1992, 20:1118-1124.
32. Takahashi T., Kitani S., Nagase M., Mochizuki M., Nishimura R., Morita Y., Sasaki N. IgG-mediated histamine release from canine mastocytoma-derived cells. Int. Arch. Allergy Immunol. 2001, 125:228-235.
33. Tsai K.L., Guyon R., Murphy K.E. Identification of isoforms and RH mapping of canine KIT. Cytogenet. Genome Res. 2003, 102:261-263.
34. Webster J.D., Kiupel M., Yuzbasiyan-Gurkan V. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer 2006, 6:85.
35. Welker P., Grabbe J., Gibbs B., Zuberbier T., Henz B.M. Human mast cells produce and differentially express both soluble and membrane-bound stem cell factor. Scand. J. Immunol. 1999, 49:495-500.
36. Welle M.M., Bley C.R., Howard J., Rufenacht S. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Vet. Dermatol. 2008, 19:321-339.
37. Yuzawa S., Opatowsky Y., Zhang Z., Mandiyan V., Lax I., Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 2007, 130:323-334.
38. Zemke D., Yamini B., Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet. Pathol. 2002, 39:529-535.